Drug Trial Radar · NCT06086912
A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites
Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Nov 7, 2023
Primary completion
Dec 12, 2023
Study completion Dec 12, 2023
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the bioavailability and safety of HR17031 injection in healthy subjects at different sites.
Conditions
- Type 2 Diabetes
Interventions
HR17031Drug
Receive a single dose of HR17031 at every period (First period:abdomen. Second period. upper arm. Third period: thigh).
HR17031Drug
Receive a single dose of HR17031 at every period (First period:upper arm. Second period: thigh. Third period: abdomen).
HR17031Drug
Receive a single dose of HR17031 at every period (First period:thigh. Second period: abdomen. Third period: upper arm).
Primary outcomes
What the sponsor says the trial is designed to measure.
- After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-t)Time frame: Start of treatment up to Day 26
- After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-∞)Time frame: Start of treatment up to Day 26
- After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Maximum Concentration (Cmax)Time frame: Start of treatment up to Day 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.